Atlas Trials

WestVac Biopharma Co., Ltd.

14 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch WestVac Biopharma Co., Ltd.

RecordFirmDate
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) (NCT07615894)WestVac Biopharma Co., Ltd.2026-06-01
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. (NCT07462468)WestVac Biopharma Co., Ltd.2026-03-10
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (NCT07170800)WestVac Biopharma Co., Ltd.2025-09-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination (NCT05911048)WestVac Biopharma Co., Ltd.2024-12-30
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination (NCT05911061)WestVac Biopharma Co., Ltd.2024-12-30
Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents (NCT05013983)WestVac Biopharma Co., Ltd.2024-07-01
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) (NCT06175494)WestVac Biopharma Co., Ltd.2023-12-19
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (NCT05465902)WestVac Biopharma Co., Ltd.2023-07-07
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (NCT05770180)WestVac Biopharma Co., Ltd.2023-03-30
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102) (NCT05765604)WestVac Biopharma Co., Ltd.2023-03-14
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster (NCT06381843)WestVac Biopharma Co., Ltd.2022-08-02
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) (NCT05465785)WestVac Biopharma Co., Ltd.2022-07-20
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster (NCT05463354)WestVac Biopharma Co., Ltd.2022-07-11

Track WestVac Biopharma Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.